MDMA-Assisted Therapy Could Improve Neurorehabilitation of Injured Service Members Beyond PTSD

A UCLA Health analysis of MDMA-assisted therapy research suggests that the drug could improve outcomes of treatment of a wider range of trauma-related conditions experienced by military personnel beyond the current focus on PTSD by increasing a collaborative and trusting relationship between a client and therapist.

The review paper, authored by UCLA Health assistant clinical professor of psychiatry Walter Dunn and published in the journal NeuroRehabilitation, explains that even in the absence of PTSD, military service members who have sustained a neurological injury in training or combat, such as a traumatic brain injury, can experience emotional and cognitive challenges that can complicate their treatment and recovery.

Dunn, a veteran of the US Marine Corps and staff psychiatrist at the Veterans Affairs Greater Los Angeles Healthcare System, says the abrupt transition, especially for young, healthy service members, from the rigorous demands of military service to facing the possibility of medical discharge, can lead to feelings of isolation, self-doubt, and other emotions that can interfere with the neurorehabilitation process.

Clinical trials of MDMA-assisted therapy in treating patients with PTSD suggest it may improve their ability to tolerate treatment and reduce dropout rates, Dunn says. The results from these trials and in other studies among healthy populations suggest the drug’s effects in facilitating social connections, improved self-esteem, and increased neural and behavioral plasticity could also benefit service members undergoing neurorehabilitation for other conditions and injuries, Dunn states.

“These are service members who are in peak physical condition, and they suddenly suffer a catastrophic injury, one that could dramatically change the course of their life,” Dunn says. “MDMA-assisted therapy could be very helpful in this context.”

Namely, Dunn says the drug’s effects could improve the relationship and trust between therapist and patient through its amplification of social reward in doses of 75 mg to 125 mg. No studies have directly investigated MDMA’s effects on therapeutic alliance in the context of neurorehabilitation. MDMA may also work to counter the impacts of low self-esteem that lead to emotional dysfunction and poor coping strategies.

Dunn also cites a need for more studies on MDMA’s effects on neuroplasticity—which is the brain’s ability to adapt and change—in humans. Mouse studies cited in the review found MDMA reduced anxiety behavior and improved working memory and social reward learning through neuroplastic mechanisms.

The review paper was published following the decision earlier this year by the FDA in August to reject an application for the use of MDMA-assisted therapy to treat PTSD. The US Drug Enforcement Agency classifies MDMA as a Schedule I narcotic, which is considered to be a drug that has “no currently accepted medical use and a high potential for abuse.”

Dunn served as a member of the FDA’s independent advisory board that reviewed the application for MDMA-assisted therapy for PTSD. Dunn was the only member who voted in favor of recommending approval of the application based on both safety and efficacy.

“By its very nature, military service involves exposure to stressful and adverse experiences. It is an inherently dangerous profession,” Dunn says. “This reality highlights the critical need for a sustained commitment to developing new treatments to support those who serve in the armed forces.”

— Source: UCLA Health